...
首页> 外文期刊>International drug discovery >Dawn of a New Era for Kinase Drug Discovery:Kinome Wide Profiling and Screeing Solutions Coupled to Functional Cell-based Assays Enable Launch of Selective and Functional Kinase Inhibitors
【24h】

Dawn of a New Era for Kinase Drug Discovery:Kinome Wide Profiling and Screeing Solutions Coupled to Functional Cell-based Assays Enable Launch of Selective and Functional Kinase Inhibitors

机译:激酶药物发现新时代的曙光:全基因组分析和筛选解决方案与基于功能性细胞的检测相结合,能够启动选择性和功能性激酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

It is no mystery that the global drug discovery market is continuously under pressure to perform against rapidly shifting regulations, timelines and performance data while balancing meaningful innovation and profitability. The industry is rising to the challenge as innovative new drug discovery technologies are fueling continuous improvements across the effectiveness of marketed drugs while minimizing potential adverse side effects. This is where novel product and service portfolios from companies like DiscoveRx~R play a pivotal role in offering a range of GPCR and Kinase based tools that give their customers the power to discover new drugs.
机译:毫无疑问,全球药物开发市场持续承受压力,要求其在迅速变化的法规,时间表和绩效数据之间取得平衡,同时平衡有意义的创新和盈利能力。随着创新的新药物发现技术推动上市药品有效性的不断提高,同时最大程度地减少潜在的不良副作用,该行业正在面临挑战。在这里,DiscoveRx〜R等公司的新颖产品和服务组合在提供一系列GPCR和基于激酶的工具方面发挥了关键作用,这些工​​具使客户能够发现新药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号